<DOC>
	<DOCNO>NCT00939627</DOCNO>
	<brief_summary>Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Sorafenib tosylate may stop growth tumor cell block enzymes need cell growth block blood flow tumor . It yet know whether cetuximab effective give alone together sorafenib tosylate treating patient head neck cancer . This randomized phase II trial study cetuximab see well work give together without sorafenib tosylate treat patient refractory , recurrent , and/or metastatic head neck cancer .</brief_summary>
	<brief_title>Phase II Randomized Trial Combination Cetuximab Sorafenib Single Agent Cetuximab</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Compare progression free survival ( PFS ) combination cetuximab sorafenib cetuximab alone patient recurrent , refractory metastatic squamous cell carcinoma head neck ( SCCHN ) . SECONDARY OBJECTIVES : I . To evaluate response rate , overall survival ( OS ) toxicity combination cetuximab sorafenib cetuximab alone . II . To evaluate presence EGFRvIII mutation , increase EGFR gene copy number activate EGFR gene expression signature , correlate clinical parameter ( RR , OS PFS ) cetuximab alone cetuximab/sorafenib arm . III . To evaluate whether VEGF receptor family ligand expression predict response cetuximab/sorafenib . IV . To determine proteomic profile serum tumor predict response survival upon treatment cetuximab cetuximab/sorafenib . V. To evaluate effect therapy general head neck specific functionality , symptom burden QOL . OUTLINE : This multicenter study . Patients randomize 1 2 treatment arm . ARM I : Patients receive cetuximab IV 60-120 minute day 1 , 8 , 15 oral placebo twice daily day 1-21 . ( oral placebo close 02/18/2010 ) . ARM II : Patients receive cetuximab IV 60-120 minute day 1 , 8 , 15 oral sorafenib tosylate twice daily day 1-21 . In arm , course repeat every 21 day absence disease progression unacceptable toxicity . Paraffin embed tissue sample collect baseline pharmacogenomic study blood sample collect baseline first 3 course research purpose . Quality life symptom burden assess Vanderbilt Head Neck Symptom Survey , FACT-HN , Fatigue Pain Inventory questionnaires baseline , day 43 , 3 6 month . After completion study treatment , patient follow periodically 3 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Laryngeal Diseases</mesh_term>
	<mesh_term>Laryngeal Neoplasms</mesh_term>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Verrucous</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Salivary Gland Neoplasms</mesh_term>
	<mesh_term>Paranasal Sinus Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Tongue Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients recurrent , refractory metastatic squamous cell carcinoma oral cavity , oropharynx larynx , hypopharynx paranasal sinus , head neck unknown primary nasopharyngeal carcinoma WHO type 1 ; patient recurrent , refractory metastatic squamous cell carcinoma oral cavity , oropharynx larynx , hypopharynx paranasal sinus , head neck unknown primary nasopharyngeal carcinoma WHO type 1 ; patient may 1 prior palliative chemotherapy recurrent metastatic disease ; please note chemotherapy give part regimen curative intent recurrent disease count `` prior chemotherapy ; '' patient must presently candidate curative therapy ECOG performance status 0 , 1 2 Hemoglobin &gt; = 9.0/dl Absoluteneutrophil count ( ANC ) &gt; = 1500/mm^3 Platelet count &gt; = 100,000/mm^3 Total bilirubin = &lt; 1.5 x ULN ALT AST = &lt; 2.5 x ULN ( = &lt; 5 x ULN patient liver involvement ) INR &lt; 1.5 PT PTT within normal limit Creatinine = &lt; 1.5 x ULN If primary therapy give curative intent , least 4 week must elapse completion primary therapy prior enrollment clinical trial ; however , toxicity prior treatment must resolve grade 1 less Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment ; woman childbearing potential men must agree use adequate contraception prior study entry duration study participation ( i.e , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study minimum 3 month follow last dose chemotherapy ; male subject agree use acceptable method contraception duration study minimum 3 month follow last dose chemotherapy Patients must measurable disease define RECIST criterion Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care ; patient legal representative must able read , understand provide inform consent participate trial Prior treatment sorafenib cetuximab Patients active clinically significant infection fever &gt; = 38.5ยบ C within 3 day first schedule day protocol treatment History prior malignancy within past 3 year except curatively treat basal cell carcinoma squamous cell carcinoma skin , CIN localize prostate cancer current PSA &lt; 1.0 mg/dL 2 successive evaluation least 3 month apart , recent evaluation within 4 week study entry Patients know hypersensitivity sorafenib cetuximab Prior severe infusion reaction monoclonal antibody History handfoot syndrome Pregnant lactating ; sexually active woman childbearing potential must use effective method birth control course study , manner risk failure minimize Known untreated brain metastasis ; patient neurological symptom must undergo CT scan/MRI brain exclude brain metastasis progression brain metastasis ; patient treat brain metastasis eligible study long evidence progression CNS disease ; hemorrhagic brain metastasis allow study Uncontrolled comorbid illness Patients HIV take antiretroviral mediation exclude potential interaction antiretroviral medication agent ; however , give potential immune modulate effect sorafenib , investigator still cautious place HIV positive patient trial effect medication HIV virus know History allogeneic transplant Patient receive investigational drug within 28 day enrollment Cardiac disease : congestive heart failure &gt; class II NYHA ; patient must unstable angina ( anginal symptom rest ) new onset angina ( begin within last 3 month ) myocardial infarction within past 6 month ; significant history uncontrolled cardiac disease ; i.e. , uncontrolled hypertension ( define define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management ) , uncontrolled congestive heart failure , cardiomyopathy decrease ejection fraction also exclude study ; cardiac ventricular arrhythmia require antiarrhythmic therapy also exclude study Thrombotic embolic event cerebrovascular accident include transient ischemic attack within past 6 month Pulmonary hemorrhage/bleeding event &gt; CTCAE grade 2 within 4 week first dose study drug Any hemorrhage/bleeding event &gt; CTCAE grade 3 within 4 week first dose study drug Tumor invade carotid artery show unequivocally image study Serious nonhealing wound , ulcer , bone fracture Evidence history bleed diathesis coagulopathy Major surgery , open biopsy significant traumatic injury within 4 week first study drug Use St. John 's Wort rifampin ( rifampicin ) Use follow medication allow within 4 week prior enrollment study study : ketoconazole , itraconazole , ritonavir , cyclosporine , carbamazepine , phenytoin , phenobarbital ; product contain grapefruit juice allow study Known suspect allergy sorafenib agent give course trial Any malabsorption problem Known HIV positive patient exclude trial due potential immune modulation agent may cause</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>